Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
COAG Catalyst Timeline
Dated clinical, regulatory and corporate events for Hemab Therapeutics Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Hemab Therapeutics Holdings, Inc.
Upcoming catalysts 2
Event history 18
Past FDA Catalysts and PDUFA Decisions
How COAG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-14 | Sutacimig (HMB-001) | Phase 2 data readout | Phase 2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HMB-002 BiologicsNCT06754852 | Von Willebrand Disease (VWD) | Phase 1/2 | RECRUITING | 108 | Jul 1, 2027 | ||||||
| HMB-003 PeptidesNCT07798505 | Undisclosed | Phase 1 | RECRUITING | 40 | Apr 30, 2027 | ||||||
| Sutacimig BiologicsNCT07935356 | Thrombasthenia | Phase 3 | RECRUITING | 76 | Jan 1, 2030 | ||||||
| Sutacimig BiologicsNCT06211634 | Glanzmann Thrombasthenia | Phase 1/2 | ACTIVE NOT_RECRUITING | 57 | Aug 1, 2027 | ||||||
| Sutacimig BiologicsNCT07347249 | Congenital Factor VII Deficiency | Phase 2 | RECRUITING | 18 | Nov 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every COAG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| sutacimig BreakthroughFast TrackOrphan | Factor VII deficiency | Phase 2b | 2026-11-04 | prothrombin time shortening: more than 50%; endogenous FVIIa accumulation: ~5x; exposure duration: through Day 22Read More | Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and ExpositionRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.10% Owner | Buy | 61,523 6,444,637 held | $24.98 | 06/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in COAG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 2.4 % (-4 %) | 240.82 M | 7.81 M |
Ownership Trends
COAG Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How COAG ranks across every disease it competes in
COAG News
Hemab Therapeutics to Participate in Upcoming Investor Conferences
Hemab Therapeutics announced participation in two upcoming investor conferences. The 2026 Jefferies Global Healthcare Conference will take place on November 17, followed by the 9th Annual Evercore Healthcare Conference on December 1. The management team will host investor meetings and provide a live webcast of their presentations.
Read more →Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Hemab Therapeutics reported positive developments in its clinical programs, including the initiation of a Phase 3 trial for sutacimig in Glanzmann thrombasthenia and the first participant dosed in a Phase 1 trial for HMB-003 targeting heavy menstrual bleeding. The company also announced promising early data for sutacimig in Factor VII deficiency. Financial results showed a net loss of $27.3 million for Q3 2026.
Read more →Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
Hemab Therapeutics has launched the SOLARA trial to evaluate sutacimig for Glanzmann thrombasthenia. This pivotal Phase 3 trial will involve approximately 75 participants and aims to reduce bleeding events. The primary endpoint is the annualized treated bleed rate. The trial follows promising Phase 2 results, although some safety concerns were noted.
Read more →Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
Hemab Therapeutics announced the presentation of clinical and preclinical data at the 68th ASH Annual Meeting. Initial results for sutacimig in Factor VII deficiency show significant accumulation of endogenous FVII(a) and reduced prothrombin time. Additionally, preclinical data for HMB-003 indicate its potential to reduce severe menstrual bleeding. Both therapies aim to address critical gaps in coagulation treatment.
Read more →Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
Hemab Therapeutics will host a conference call on November 10, 2026, at 8:00 a.m. ET to discuss its third-quarter financial results and provide a corporate update. The company focuses on developing therapies for blood coagulation disorders, with several innovative treatments in clinical development. A replay of the call will be available for 90 days post-event.
Read more →Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
Hemab Therapeutics has appointed Keli Walbert to its Board of Directors, effective September 24, 2026. Walbert, who brings over 20 years of commercial leadership experience, will join the Audit Committee and replace Akshay Vaishnaw. Her background in launching therapies for various diseases is expected to strengthen Hemab's efforts in developing treatments for bleeding disorders.
Read more →Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
Hemab Therapeutics has initiated a Phase 1 clinical trial for HMB-003, a novel therapy aimed at managing heavy menstrual bleeding. This investigational treatment, designed to inhibit plasmin and stabilize blood clots, has shown promising results in preclinical studies. The trial aims to evaluate its safety and pharmacokinetics, with results expected by mid-2027.
Read more →Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Hemab Therapeutics reported second quarter 2026 financial results and provided a corporate update. The FDA endorsed sutacimig data for a Phase 3 trial in Glanzmann thrombasthenia, with initiation planned for the second half of 2026. New data for HMB-002 showed a 2.4-fold increase in Von Willebrand Factor and Factor VIII levels. The company also unveiled HMB-003, a new plasmin inhibitor for heavy menstrual bleeding.
Read more →Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
Hemab Therapeutics presented promising clinical and preclinical data for sutacimig at the ISTH 2026 Congress, showing significant bleed reduction in patients with Glanzmann thrombasthenia and Factor VII deficiency. The Phase 2 long-term extension data indicated a manageable safety profile and FDA agreement on advancing to Phase 3 trials. Additionally, preclinical findings suggest sutacimig's broad applicability in treating bleeding disorders.
Read more →Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
Hemab Therapeutics presented promising clinical data for HMB-002 in treating Von Willebrand Disease and introduced HMB-003 for heavy menstrual bleeding at the ISTH 2026 Congress. HMB-002 demonstrated significant increases in Von Willebrand Factor and Factor VIII, supporting its potential for monthly dosing. HMB-003 is designed as a non-hormonal antifibrinolytic to address heavy menstrual bleeding, aiming to provide effective treatment options for women.
Read more →Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
Hemab Therapeutics announced significant advancements in its blood coagulation programs, including promising first-in-human data for HMB-002 in Von Willebrand disease and the introduction of HMB-003, a new peptide plasmin inhibitor. The company plans to present nine studies at the ISTH 2026 Congress, showcasing its commitment to addressing critical gaps in coagulation disorder treatments. Sutacimig has also received FDA Breakthrough Therapy designation, with a Phase 3 trial expected to begin in the second half of 2026.
Read more →Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Hemab Therapeutics will participate in the 2026 Jefferies Global Healthcare Conference, where its management team will present and hold investor meetings. The event is scheduled for June 4, 2026, in New York, NY. Hemab is focused on developing therapies for blood coagulation disorders, including treatments for Glanzmann thrombasthenia and Von Willebrand Disease.
Read more →Hemab Therapeutics Reports First Quarter 2026 Financial Results
Hemab Therapeutics has reported its first quarter financial results for 2026, highlighting the successful completion of an initial public offering that raised $346.7 million and secured a listing on Nasdaq. The company received Breakthrough Therapy Designation for sutacimig, a bispecific antibody for Glanzmann thrombasthenia. Despite these advancements, Hemab reported a net loss of $22.687 million in the quarter, with a decrease in cash reserves compared to the previous quarter.
Read more →Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Hemab Therapeutics Holdings, Inc. has successfully closed its upsized initial public offering, selling 19,262,500 shares at $18.00 each. The offering generated approximately $346.7 million in gross proceeds. The company's stock began trading on the Nasdaq Global Select Market under the ticker COAG. The underwriters fully exercised their option to purchase additional shares.
Read more →Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
Hemab Therapeutics Holdings, Inc. has announced the pricing of its initial public offering, offering 16,750,000 shares at $18.00 each. The IPO is expected to generate around $301.5 million in gross proceeds. Trading is set to begin on the Nasdaq Global Select Market under the ticker 'COAG' on May 1, 2026, with the offering closing around May 4, 2026.
Read more →